RVNC - Revance Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
811
3,729
262
300
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
100,900
92,500
80,361
50,381
Selling General and Administrative
56,603
53,863
37,398
29,075
Total Operating Expenses
157,503
146,363
117,759
79,456
Operating Income or Loss
-156,692
-142,634
-117,497
-79,156
Interest Expense
0
44
457
1,082
Total Other Income/Expenses Net
-446
-913
-4,043
-10,202
Income Before Tax
-151,719
-139,568
-120,587
-89,270
Income Tax Expense
-
3,000
-
-
Income from Continuing Operations
-154,719
-142,568
-120,587
-89,270
Net Income
-154,719
-142,568
-120,587
-89,270
Net Income available to common shareholders
-154,719
-142,568
-120,587
-89,270
Reported EPS
Basic
-
-3.94
-4.01
-3.18
Diluted
-
-3.94
-4.01
-3.18
Weighted average shares outstanding
Basic
-
36,172
30,101
28,115
Diluted
-
36,172
30,101
28,115
EBITDA
-
-139,524
-118,662
-86,743